Predicting the Response to Chemotherapy in Gastric Adenocarcinoma: Who Benefits from Neoadjuvant Chemotherapy?

摘要: Despite a decline in the overall incidence, gastric adenocarcinoma remains second most common cause of cancer death worldwide and thus significant global health problem. Even early-stage locoregional confined disease 5-year survival rarely exceeds 25–35 %. Randomized trials have demonstrated benefit from neoadjuvant perioperative chemotherapy. However optimal approach individual patients is not clear controversial. A consistent finding that who histopathological response to therapy are more likely receive benefit. These clinical data provide strong argument for urgent development methods predict therapies adenocarcinomas. Published demonstrate clinico-pathological features (tumour histology location), imaging through metabolic by FDG-PET tissue/molecular biomarkers may all predictive value therapies. it still uncertain published whether or they will be useful decision making patients. Existing candidate need properly qualified validated novel required an should involve combination integration clinical, imaging, pathological molecular biomarkers.